Glofitamab Emerges as an Accessible, High-Potential Alternative to CAR T Therapy in DLBCL
Key Takeaways:
Glofitamab is more accessible: Glofitamab has fewer access barriers for patients with diffuse large B-cell lymphoma (DLBCL) as it does not require specialized centers, unlike chimeric antigen receptor (CAR) T-cell therapy.
Glofitamab shows promising curative potential: The efficacy rates of glofitamab are favorable, especially for patients who have achieved complete response (CR). Future research could reveal it to be a curative treatment for DLBCL.
Glofitamab has a comparable safety profile: When used to treat mantle cell lymphoma (MCL), glofitamab resulted in fewer instances of immune effector cell-associated neurotoxicity syndrome (ICANS). Cytokine release syndrome (CRS) is still a concern, but current studies are looking for ways to reduce the risk of this complication.
Dr Tycel Phillips, MD, associate editor of Blood Cancers Today, wrote an editorial letter about how the development of the bispecific antibody glofitamab can improve treatment and outcomes for patients with DLBCL.
The biggest benefit of glofitamab is that it is more accessible than other treatment options. CAR T-cell therapy has proven to be an effective treatment for DLBCL and has resulted in favorable patient outcomes, but access to it is blocked by many barriers. Glofitamab, on the other hand, can be provided in community settings, making it more accessible for patients.
Not only is glofitamab more accessible, but it has promising efficacy rates as well. Recent studies with this bispecific antibody have shown encouraging CR rates and durable responses. According to Dr Phillips, current research is on the cusp of evaluating the curative potential of glofitamab, which could lead to huge strides in treating DLBCL.
Dr Phillips said, “If we can show that glofitamab is curative in patients who achieve a complete response, this would allow the treatment to be used in lieu of CAR T-cells for patients who are unable to reach or remain at a specialized center for the required duration.”
One study used glofitamab to treat MCL and recorded a safety profile that is comparable with CAR T therapy. Events of ICANS occurred in less than 10% of patients, and these events were mostly low grade (grade 1 or 2). However, Dr Phillips admits that CRS is still a concern for patients with DLBCL, even for those who are treated with glofitamab. Current studies are evaluating different combination and dose strategies to reduce the risk of CRS.
Bispecific antibodies, particularly glofitamab, have shown to be more effective than rituximab at treating patients with DLBCL. Dr Phillips believes that establishing glofitamab in earlier lines of therapy could majorly improve outcomes by increasing cure rates and extending remission for patients with DLBCL.
Reference
Phillips T. Developing Glofitamab: The future of B-cell lymphoma. Blood Cancers Today. January 26, 2026. Accessed April 29, 2026. https://www.bloodcancerstoday.com/post/developing-glofitamab-the-future-of-b-cell-lymphoma.
